Latest Breaking News On - Yuhan corp - Page 4 : comparemela.com

To embed, copy and paste the code into your website or blog: During the first quarter of 2021, multiple companies launched adalimumab biosimilars as a growing number of biosimilar players marketed their versions of the world’s most profitable drug, Humira ®, which had sales of about $20 billion in 2020. While none have launched thus far, at least eight adalimumab biosimilars are due to launch by the end of 2023 in the United States, where Abbvie secured over $16 billion of its Humira ® sales revenues in 2020. On February 11, 2021, the European Commission (EC) granted marketing authorization for Celltrion’s Yuflyma TM for use in treating thirteen chronic inflammatory diseases. This authorization is valid in all EU Member States and the European Economic Area countries Iceland, Liechtenstein, and Norway. According to Celltrion, Yuflyma

United statesCelltrion yuflymaSamsung bioepisFresenius kabiCanadian pharmaceutical allianceJapan health ministryHealth canada onYuhan corpEuropean commissionEuropean economic areaSandoz canadaHealth canadaFresenius kabi canadaNorth americaHealth ministryஒன்றுபட்டது மாநிலங்களில்